Fig. 3From: A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapyReduction of low-density lipoprotein cholesterol (LDL-C) and sitting systolic blood pressure (SiSBP) from baseline at week 8. A Percent change from baseline in LDL-C. B Change from baseline in SiSBPBack to article page